BioLife Solutions announced its Q3 2023 financial results, with total revenue of $33.3 million. The company is focusing on adapting and innovating as a leading provider of cell processing tools and biostorage services, with a strategic emphasis on the high-margin, recurring biopreservation media revenue.
Total revenue for Q3 2023 was $33.3 million, an 18% decrease from Q3 2022.
Cell Processing platform revenue was $13.3 million, a 26% decrease year-over-year
Biostorage and Services platform revenue was $6.6 million, a 10% decrease year-over-year, but ex-COVID related revenue grew 50%.
The company is working on the divestiture of the freezer operations, expected to conclude in early 2024.
BioLife Solutions anticipates full year 2023 revenue to be at the low end of the previously announced guidance range of $144 million to $158 million. Revenue expectations include approximately $65 million from the Cell Processing platform, $26 million from the Biostorage and Services platform, and $53 million from the Freezers and Thaw Systems platform.
Visualization of income flow from segment revenue to net income